International Journal of Cancer Management

Published by: Kowsar

The Prevalence and Associated Factors of Microsatellite Instability in Ovarian Epithelial Cancers Detected by Molecular Genetic Studies in a Sample of Iranian Women

Reza Shahsiah 1 , Samaneh Salarvand 1 , * , Rosa Miri 1 , Reza Ghalehtaki 2 and Nasser Rakhshani 3
Authors Information
1 Department of Anatomical and Clinical Pathology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
2 Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Anatomical and Clinical Pathology, Iran University of Medical Sciences, Tehran, Iran
Article information
  • International Journal of Cancer Management: December 2017, 10 (12); e11599
  • Published Online: December 31, 2017
  • Article Type: Research Article
  • Received: April 5, 2017
  • Revised: October 3, 2017
  • Accepted: December 12, 2017
  • DOI: 10.5812/ijcm.11599

To Cite: Shahsiah R, Salarvand S, Miri R, Ghalehtaki R, Rakhshani N. The Prevalence and Associated Factors of Microsatellite Instability in Ovarian Epithelial Cancers Detected by Molecular Genetic Studies in a Sample of Iranian Women, Int J Cancer Manag. 2017 ; 10(12):e11599. doi: 10.5812/ijcm.11599.

Copyright © 2017, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Alvi AJ, Rader JS, Broggini M, Latif F, Maher ER. Microsatellite instability and mutational analysis of transforming growth factor beta receptor type II gene (TGFBR2) in sporadic ovarian cancer. Mol Pathol. 2001;54(4):240-3. [PubMed: 11477138].
  • 2. Dellas A, Puhl A, Schraml P, Thomke SE, Ruschoff J, Mihatsch MJ, et al. Molecular and clinicopathological analysis of ovarian carcinomas with and without microsatellite instability. Anticancer Res. 2004;24(1):361-9. [PubMed: 15015622].
  • 3. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247-57. doi: 10.1056/NEJMoa022289. [PubMed: 12867608].
  • 4. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 1997;57(21):4749-56. [PubMed: 9354436].
  • 5. Caliman LP, Tavares RL, Piedade JB, D. E. Assis AC , D. E. Jesus Dias DA Cunha K , Braga LD, et al. Evaluation of microsatellite instability in women with epithelial ovarian cancer. Oncol Lett. 2012;4(3):556-60. doi: 10.3892/ol.2012.776. [PubMed: 22970055].
  • 6. Massey A, Offman J, Macpherson P, Karran P. DNA mismatch repair and acquired cisplatin resistance in E. coli and human ovarian carcinoma cells. DNA Repair (Amst). 2003;2(1):73-89. [PubMed: 12509269].
  • 7. Esmailnia G, Haghighi MM, Javadi G, Parivar K, Zali MR. Microsatellite instability markers status in colorectal cancer. Zahedan J Res Med Sci. 2014;16(12):26–30.
  • 8. Murphy KM, Zhang S, Geiger T, Hafez MJ, Bacher J, Berg KD, et al. Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn. 2006;8(3):305-11. doi: 10.2353/jmoldx.2006.050092. [PubMed: 16825502].
  • 9. Bacher JW, Flanagan LA, Smalley RL, Nassif NA, Burgart LJ, Halberg RB, et al. Development of a fluorescent multiplex assay for detection of MSI-High tumors. Dis Markers. 2004;20(4-5):237-50. [PubMed: 15528789].
  • 10. Buhard O, Suraweera N, Lectard A, Duval A, Hamelin R. Quasimonomorphic mononucleotide repeats for high level microsatellite instability analysis. Dis Markers. 2004;20(4-5):251-7. doi: 10.1155/2004/159347.
  • 11. Buhard O, Cattaneo F, Wong YF, Yim SF, Friedman E, Flejou JF, et al. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol. 2006;24(2):241-51. doi: 10.1200/JCO.2005.02.7227. [PubMed: 16330668].
  • 12. Xicola RM, Llor X, Pons E, Castells A, Alenda C, Pinol V, et al. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst. 2007;99(3):244-52. doi: 10.1093/jnci/djk033. [PubMed: 17284719].
  • 13. Pal T, Permuth-Wey J, Kumar A, Sellers TA. Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin Cancer Res. 2008;14(21):6847-54. doi: 10.1158/1078-0432.CCR-08-1387. [PubMed: 18980979].
  • 14. Pal T, Permuth-Wey J, Sellers TA. A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer. Cancer. 2008;113(4):733-42. doi: 10.1002/cncr.23601. [PubMed: 18543306].
  • 15. Liu J, Albarracin CT, Chang KH, Thompson-Lanza JA, Zheng W, Gershenson DM, et al. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol. 2004;17(1):75-80. doi: 10.1038/sj.modpathol.3800017. [PubMed: 14631366].
  • 16. Murphy MA, Wentzensen N. Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America. Int J Cancer. 2011;129(8):1914-22. doi: 10.1002/ijc.25835. [PubMed: 21140452].
  • 17. Lu FI, Gilks CB, Mulligan AM, Ryan P, Allo G, Sy K, et al. Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors. Int J Gynecol Pathol. 2012;31(6):524-31. doi: 10.1097/PGP.0b013e31824fe2aa. [PubMed: 23018216].
  • 18. Vierkoetter KR, Ayabe AR, VanDrunen M, Ahn HJ, Shimizu DM, Terada KY. Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary. Gynecol Oncol. 2014;135(1):81-4. doi: 10.1016/j.ygyno.2014.07.100. [PubMed: 25093288].
  • 19. Zhai QJ, Rosen DG, Lu K, Liu J. Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is histotype-specific. Int J Clin Exp Pathol. 2008;1(6):502-9. [PubMed: 18787632].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments